Primary Mediastinal B-Cell Lymphoma

Future directions

• PD-L1++
  • KEYNOTE-170
    • pembro monotherapy for R/R PMBCL
    • N=53, median LoT 3 (26.4% ASCT)
    • ORR 41.5%, CR 20.8%, mOS 22.3mo, 4y OS 45.3%
  • --> frontline chemo + pembro
    • NCT04759586 (investigator's choice + pembro)
• Cellular therapy
  • e.g. ZUMA-1
    • axi-cel CAR-T
    • N=101, R/R LCL, 8% PMBCL
    • ORR 83%, CR 58%, mOS 25.8mo, 5y OS 42.6%